85 results
8-K
EX-1.1
RVNC
Revance Therapeutics Inc
5 Mar 24
Other Events
5:08pm
of its subsidiaries, individually or in the aggregate, have a Material Adverse Effect.
(w) Environmental Laws. Except as disclosed in the General … to the protection or restoration of the environment or human exposure to hazardous or toxic substances (collectively, “environmental laws”), owns or operates
424B5
RVNC
Revance Therapeutics Inc
5 Mar 24
Prospectus supplement for primary offering
5:00pm
dystonia and glabellar lines;
anticipated milestone payments;
our human capital, social and environmental performance and goals;
our ability to expand
424B5
RVNC
Revance Therapeutics Inc
4 Mar 24
Prospectus supplement for primary offering
6:39am
approval of DAXXIFY® for cervical dystonia and glabellar lines;
anticipated milestone payments;
our human capital, social and environmental performance
S-3ASR
dl10cp0x
14 Nov 23
Automatic shelf registration
4:22pm
8-K
EX-1.1
kfp9tl8ou3izrel6j2i
13 Sep 22
Other Events
9:55pm